What does the F2-isoprostane (F2-isoprostane)/Creatinine ratio indicate in a patient with a history of metabolic syndrome or cardiovascular disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 13, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

F2-Isoprostane/Creatinine Ratio: Clinical Significance

The F2-isoprostane/creatinine ratio is a biomarker of systemic oxidative stress that is markedly elevated in patients with metabolic syndrome and cardiovascular disease, reflecting in vivo lipid peroxidation and correlating with insulin resistance, adiposity, and inflammation. 1

What This Ratio Measures

  • Direct quantification of oxidative stress: F2-isoprostanes are prostaglandin-like compounds produced by free radical-mediated oxidation of arachidonic acid, making them chemically stable and highly specific markers of in vivo lipid peroxidation 2, 3

  • Normalization to creatinine: The ratio to urinary creatinine accounts for variations in urine concentration and provides a standardized measure across different collection times 4, 3

  • Superior to indirect measures: F2-isoprostane measurement provides direct assessment of oxidative stress and appears superior to indirect measures like LDL oxidative susceptibility in type 2 diabetes 4

Clinical Significance in Metabolic Syndrome

Adults with metabolic syndrome demonstrate nearly 4-fold elevation in plasma F2-isoprostanes compared to those with normal lipids and normal weight. 1

  • Correlation with metabolic parameters: F2-isoprostane levels correlate with adiposity and insulin sensitivity, with the combination of high BMI and insulin resistance associated with the highest levels 1

  • Dose-response relationship: Studies demonstrate a dose-effect where patients with metabolic abnormalities have higher isoprostane levels compared to overweight patients without metabolic abnormalities, who in turn have higher levels than normal-weight controls 1

  • Association with inflammation: Plasma F2-isoprostanes correlate with C-reactive protein levels (r = 0.48, P = 0.015), demonstrating the link between oxidative stress and systemic inflammation 5

Cardiovascular Disease Context

  • Mechanistic role in atherosclerosis: Oxidative stress mediates plaque rupture and thrombosis, with oxidized LDL being toxic to vasculature 1

  • Elevated in renal artery disease: Patients with renovascular hypertension have elevated F2-isoprostanoids, which contribute to hypertension, renal injury, and possible cardiac injury 1

  • Biological activity: F2-isoprostanes possess potent biological activities, including renal vasoconstriction (8-iso-PGF2α), suggesting they act as mediators rather than just markers of oxidative stress 2

Important Limitations and Caveats

Measures of oxidative stress are not shown to predict future CVD events in observational studies, and no interventional trials altering oxidative stress have affected CVD event rates. 1

  • Not clinically validated: Oxidative stress is not measured clinically in adults or children for risk stratification or treatment decisions 1

  • Lack of standardization: Each assay represents a different aspect of the oxidative stress process, and there is no agreed-upon indicator for oxidative stress 1

  • Renal function confounding: In patients with chronic kidney disease, impaired clearance of esterified F2-isoprostanes may contribute to elevated levels independent of oxidative stress severity 5

  • Paradoxical findings in CKD: Urinary F2-isoprostanes are highest in early CKD (stage 1) and decrease significantly with advancing renal failure, inversely correlating with serum creatinine (r = -0.66), likely due to reduced renal clearance mechanisms 6

Practical Interpretation

  • Normal reference range: Spot urine F2-isoprostane levels in healthy subjects average 38.1 ± 19.1 ng/mg creatinine 3

  • Hemodialysis patients: Show up to 6-fold increase in plasma F2-isoprostanes (1.62 ± 0.73 ng/mL vs 0.27 ± 0.10 ng/mL in controls) with no overlap between patients and controls 2, 5

  • Type 2 diabetes: Baseline concentrations are significantly higher in diabetics with and without macrovascular complications compared to controls (P <0.001) 4

  • Response to antioxidants: Alpha-tocopherol supplementation significantly reduces F2-isoprostane concentrations in diabetic patients (2.51 ± 1.76 to 1.69 ± 1.32 ng/mg creatinine; P <0.001), demonstrating the marker's responsiveness to interventions 4

Current Clinical Role

The F2-isoprostane/creatinine ratio remains a research tool rather than a clinical diagnostic test, as much remains to be done before we can understand how oxidative stress relates to cardiovascular outcomes and whether interventions targeting this pathway improve morbidity or mortality. 1

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

What is the recommended oral step-down therapy for a patient with Community-Acquired Pneumonia (CAP) due to Multi-Drug Resistant (MDR) pathogens who has shown improvement on Intravenous (IV) Ceftriaxone?
What is the best course of action for a 44-year-old female patient with chronic constipation, who has a history of a colon full of stool as seen on a computed tomography (CT) scan during an emergency department (ED) visit, reports passing thin stools only once every two weeks, and has failed treatment with stool softeners, enemas, and Miralax (polyethylene glycol 3350)?
What are the symptoms and treatment options for a patient with a blood clot, particularly those with a history of deep vein thrombosis (DVT) or pulmonary embolism (PE)?
What is the recommended treatment for a patient with pneumonia being considered for outpatient treatment, considering their medical history and severity of symptoms?
What is the recommended management for a patient presenting with symptoms necessitating a Lanz incision, likely due to appendicitis or another acute abdominal condition?
What are the definition and criteria for chronic respiratory failure and mechanical ventilation (MV) dependence?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question